Jue Pu
Directeur/Membre du Conseil chez LEPU BIOPHARMA CO., LTD.
Fortune : 63 M $ au 30/04/2024
Postes actifs de Jue Pu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| LEPU BIOPHARMA CO., LTD. | Directeur/Membre du Conseil | 22/04/2020 | - |
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/10/2018 | - |
Historique de carrière de Jue Pu
Anciens postes connus de Jue Pu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CG ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/03/2019 | 01/10/2023 |
| CG ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/01/2010 | 01/01/2018 |
| Fondateur | 01/01/2010 | 01/01/2018 |
Formation de Jue Pu
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
| Stanford University | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Chine | 2 |
Opérationnelle
| Director/Board Member | 4 |
| Founder | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CG ONCOLOGY, INC. | Health Technology |
| LEPU BIOPHARMA CO., LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Health Technology |
